12 recruiting, 6 completed, 5 terminated, 2 active not recruiting. 12 Phase 1, 11 Phase 2, 6 Not applicable, 1 Early Phase 1, 1 Phase 4.
Follow Relapsed Cancer: new trials by email Literature Review of Relapsed Cancer trials Research Report on Relapsed Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors Bulk RNA Sequencing, Immunohistochemistry (IHC) - CNS Tumor, Solid Tumor | Not applicable | Not yet recruiting | Dana-Farber Cancer Institute | 130 | 2026-09-01 | 2026-08-31 |
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Three Times Weekly Symptom Screening for Children With Cancer SPARK - Cancer, Relapsed Cancer | Not applicable | Not yet recruiting | The Hospital for Sick Children | 30 | 2025-08-01 | 2025-05-15 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| Plan Development for Giving Teclistamab in the Outpatient Setting Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer | Phase 4 | Recruiting | University Health Network, Toronto | 15 | 2024-11-19 | 2025-12-10 |
| Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) - Cancer, Malignancy | Phase 1 | Recruiting | CytoMed Therapeutics Pte Ltd | 12 | 2024-11-19 | 2024-11-22 |
| Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma Isatuximab, Belantamab mafodotin, Pomalidomide - Relapsed Cancer, Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 50 | 2024-05-31 | 2026-01-14 |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT) - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Recruiting | Baptist Health South Florida | 15 | 2024-04-25 | 2026-03-03 |
| Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma Relapsed glioblastoma - Relapsed Cancer, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Recruiting | University Hospital, Bordeaux | 40 | 2024-04-05 | 2025-07-30 | |
| Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) Adaptive Bridging Radiation Therapy (ABRT) - Lymphoma, B-Cell, Relapsed Cancer | Not applicable | Completed | Massachusetts General Hospital | 10 | 2024-01-14 | 2026-10-15 |
| Individualized Treatments in Adults With Relapsed/Refractory Cancers Drug Sensitivity Test (DST) - Refractory Cancer, Relapsed Cancer | Not applicable | Completed | Case Comprehensive Cancer Center | 36 | 2023-11-20 | 2026-07-06 |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab - Large Cell Lymphoma, Diffuse, Relapsed Cancer | Phase 2 | Recruiting | Dipenkumar Modi | 35 | 2023-10-31 | 2026-07-10 |
| A Biomarker Screening Protocol for Participants With Solid Tumors Triple Negative Breast Cancer, Non-small Cell Lung Cancer | Terminated | Lyell Immunopharma, Inc. | 10 | 2023-05-19 | 2025-07-01 | |
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody HST-1011, Cemiplimab - Solid Tumor, Adult, Relapsed Cancer | Phase 1 / Phase 2 | Active not recruiting | HotSpot Therapeutics, Inc | 77 | 2023-03-15 | 2025-02-04 |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab - Multiple Myeloma, Relapsed Cancer | Phase 1 | Terminated | Anaveon AG | 4 | 2023-02-10 | 2024-02-12 |
| Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer BMF-219 - Non Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Terminated | Biomea Fusion Inc. | 13 | 2023-01-12 | 2025-02-07 |
| Precision Medicine for Every Child With Cancer Whole Genome Sequencing, RNA seq, DNA Methylation - Childhood Cancer, Childhood Solid Tumor | Recruiting | Australian & New Zealand Children's Haematology/Oncology Group | 3500 | 2022-12-16 | 2024-07-17 | |
| myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports Cellworks Report - Cancer, Relapsed Cancer | Unknown | Cellworks Group Inc. | 730 | 2022-12-01 | 2023-01-23 | |
| A Study to Investigate LYL797 in Adults With Solid Tumors LYL797 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 | Terminated | Lyell Immunopharma, Inc. | 57 | 2022-03-29 | 2025-07-01 |
Showing 20 of 29. Sign in to see all of them.
Recurrence (29) · Neoplasms (22) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Multiple Myeloma (3) · Neoplasm Metastasis (3) · Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (2) · Central Nervous System Neoplasms (2) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Glioblastoma (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Lymphoma, B-Cell (2)
Disease Attributes (29) · Pathologic Processes (29) · Pathological Conditions, Signs and Symptoms (29) · Neoplasms by Histologic Type (13) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms (7) · Neoplasms by Site (7) · Hematologic Diseases (6) · Lymphatic Diseases (5) · Lung Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Respiratory Tract Diseases (4)
pembrolizumab (3) · Dexamethasone (2) · Rituximab (2) · venetoclax (2) · zanubrutinib (2) · Automobiles (1) · Base Sequence (1) · Bendamustine Hydrochloride (1) · Biopsy (1) · Crizotinib (1) · DNA Methylation (1) · Decitabine (1) · Guanosine Diphosphate (1) · High-Throughput Nucleotide Sequencing (1) · Immunohistochemistry (1)
University Health Network, Toronto (4) · Massachusetts General Hospital (3) · Dana-Farber Cancer Institute (2) · Lyell Immunopharma, Inc. (2) · Vanderbilt-Ingram Cancer Center (2) · Anaveon AG (1) · Australian & New Zealand Children's Haematology/Oncology Group (1) · Baptist Health South Florida (1) · BeOne Medicines (1) · Biomea Fusion Inc. (1) · Case Comprehensive Cancer Center (1) · Cellworks Group Inc. (1) · Children's Hospital Medical Center, Cincinnati (1) · CytoMed Therapeutics Pte Ltd (1) · Dipenkumar Modi (1)
United States (19) · Canada (6) · Australia (3) · France (2) · Germany (2) · New Zealand (2) · Spain (2) · Brazil (1) · China (1) · Denmark (1) · Italy (1) · Poland (1) · Singapore (1) · South Korea (1) · Switzerland (1)
Jackie Walling, MBChB, PhD (2) · Maryjo Gilmer, PhD (2) · Alison O'Neill, MD (1) · Anand D Jeyasekharan, Dr (1) · Andrew Yee, MD (1) · Brian Turpin, DO (1) · Chirayu Patel, MD (1) · Christine Chen, Dr. (1) · David Ziegler (1) · Diana Azzam, PhD (1) · Dipenkumar Modi, MD (1) · Eduard Gasal, MD (1) · Ibiayi Dagogo-Jack, MD (1) · Jennifer Brown, MD, PhD (1)
PMID 32580982, PMID 34927159, PMID 36882456, PMID 37751186, PMID 38844796, PMID 38898768, PMID 40178467, PMID 40209140, PMID 41075807, PMID 42399266
R21HD097757 (1)